Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
Heterologous expression systems have increased the feasibility of developing selective ligands to target nicotinic acetylcholine receptor (nAChR) subtypes. However, the alpha6 subunit, a component in nAChRs that mediates some of the reinforcing effects of nicotine, is not easily expressed in systems such as the Xenopus oocyte. Certain aspects of alpha6-containing receptor pharmacology have been studied by using chimeric subunits containing the alpha6 ligand-binding domain. However, these chimeras would not be sensitive to an alpha6-selective channel blocker; therefore we developed an alpha6 chimera (alpha4/6) that has the transmembrane and intracellular domains of alpha6 and the extracellular domain of alpha4. We examined the pharmacological properties of alpha4/6-containing receptors and other important nAChR subtypes, including alpha7, alpha4beta2, alpha4beta4, alpha3beta4, alpha3beta2, and alpha3beta2beta3, as well as receptors containing alpha6/3 and alpha6/4 chimeras. Our data show that the absence or presence of the beta4 subunit is an important factor for sensitivity to the ganglionic blocker mecamylamine, and that dihydro-beta-erythroidine is most effective on subtypes containing the alpha4 subunit extracellular domain. Receptors containing the alpha6/4 subunit are sensitive to alpha-conotoxin PIA, while receptors containing the reciprocal alpha4/6 chimera are insensitive. In experiments with novel antagonists of nicotine-evoked dopamine release, the alpha4/6 chimera indicated that structural rigidity was a key element of compounds that could result in selectivity for noncompetitive inhibition of alpha6-containing receptors. Our data extend the information available on prototypical nAChR antagonists, and establish the alpha4/6 chimera as a useful new tool for screening drugs as selective nAChR antagonists.
Ayers,
bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.
2002, Pubmed
Ayers,
bis-Azaaromatic quaternary ammonium analogues: ligands for alpha4beta2* and alpha7* subtypes of neuronal nicotinic receptors.
2002,
Pubmed Azam,
Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons.
2007,
Pubmed Azam,
Characterization of nicotinic acetylcholine receptors that modulate nicotine-evoked [3H]norepinephrine release from mouse hippocampal synaptosomes.
2006,
Pubmed Bouzat,
Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel.
2004,
Pubmed Charpantier,
Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area.
1998,
Pubmed Chavez-Noriega,
Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase Clarke,
Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin.
1985,
Pubmed Cordero-Erausquin,
Nicotinic receptor function: new perspectives from knockout mice.
2000,
Pubmed Crooks,
Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
2004,
Pubmed Damaj,
In vivo characterization of a novel inhibitor of CNS nicotinic receptors.
2005,
Pubmed Dowell,
Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase Dwoskin,
Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
2004,
Pubmed Evans,
Expression and functional characterisation of a human chimeric nicotinic receptor with alpha6beta4 properties.
2003,
Pubmed
,
Xenbase Francis,
Sensitivity to voltage-independent inhibition determined by pore-lining region of the acetylcholine receptor.
1998,
Pubmed
,
Xenbase Gerzanich,
alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors.
1998,
Pubmed
,
Xenbase Göldner,
Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area.
1997,
Pubmed Gotti,
Brain nicotinic acetylcholine receptors: native subtypes and their relevance.
2006,
Pubmed Kuryatov,
Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses.
2000,
Pubmed
,
Xenbase Le Novère,
Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain.
1996,
Pubmed Luetje,
Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors.
1991,
Pubmed
,
Xenbase Lummis,
Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel.
2005,
Pubmed McIntosh,
Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.
2004,
Pubmed
,
Xenbase Miller,
Genetic manipulation of ion channels: a new approach to structure and mechanism.
1989,
Pubmed Nai,
Relating neuronal nicotinic acetylcholine receptor subtypes defined by subunit composition and channel function.
2003,
Pubmed Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase Neugebauer,
Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
2006,
Pubmed Olincy,
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
2006,
Pubmed Palma,
Effects of Zn2+ on wild and mutant neuronal alpha7 nicotinic receptors.
1998,
Pubmed
,
Xenbase Papke,
Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes.
2001,
Pubmed
,
Xenbase Papke,
Inhibition of wild-type and mutant neuronal nicotinic acetylcholine receptors by local anesthetics.
2001,
Pubmed
,
Xenbase Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase Papke,
The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4-yl heptanoate.
2005,
Pubmed
,
Xenbase Papke,
Inhibition of nicotinic acetylcholine receptors by bis (2,2,6,6-tetramethyl- 4-piperidinyl) sebacate (Tinuvin 770), an additive to medical plastics.
1994,
Pubmed
,
Xenbase Papke,
Mechanisms of noncompetitive inhibition of acetylcholine-induced single-channel currents.
1989,
Pubmed Papke,
The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery.
2007,
Pubmed
,
Xenbase Potts,
Varenicline: the newest agent for smoking cessation.
2007,
Pubmed Rahman,
Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.
2008,
Pubmed
,
Xenbase Rose,
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.
1994,
Pubmed Salminen,
Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice.
2007,
Pubmed Salminen,
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.
2004,
Pubmed Sanberg,
Treatment of Tourette's syndrome with mecamylamine.
1998,
Pubmed Stokes,
The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors.
2004,
Pubmed
,
Xenbase STONE,
Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine.
1956,
Pubmed Webster,
Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain.
1999,
Pubmed
,
Xenbase Wilens,
ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
2006,
Pubmed Zheng,
Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
2007,
Pubmed Zoli,
Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum.
2002,
Pubmed
